This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $546.57 in the latest trading session, marking a -0.79% move from the prior day.
Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion
by Ekta Bagri
Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug
by Zacks Equity Research
If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.
Market Bears Take The Bulls By The Horns As Q4 Kicks Off
by Daniel Laboe
We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows
Gilead (GILD) Tecartus Gets FDA Nod for Leukemia Indication
by Zacks Equity Research
Following FDA approval, Gilead's (GILD) Tecartus becomes the first and only CAR T-cell therapy approved for treating relapsed/refractory B-cell acute lymphoblastic leukemia in adult patients.
Here's Why Regeneron (REGN) is Poised for a Turnaround After Losing 16% in 4 Weeks
by Zacks Equity Research
Regeneron (REGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
5 Must-Buy Stocks for Q4 With Strong Growth Potential
by Nalak Das
We have narrowed down our search to five large-cap stocks that have strong growth potential for the fourth quarter. These are: NUE, STLD, TSLA, KKR and REGN.
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Core PCE Inflation Stays at Record-High in August
by Zacks Equity Research
Core PCE Inflation Stays at Record-High in August.
Merck (MRK) Develops Pill to Lessen Covid Symptoms
by Mark Vickery
Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.
Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal
by Zacks Equity Research
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.
Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022
by Zacks Equity Research
Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.
Regeneron (REGN) Reports Positive Data on Antibody Cocktail
by Zacks Equity Research
Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.
Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA
by Zacks Equity Research
Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
Ziopharm (ZIOP) Down on Workforce Reduction Announcement
by Zacks Equity Research
Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.
Regeneron's (REGN) sBLA for Libtayo Gets Priority Review
by Zacks Equity Research
Regeneron's (REGN) application seeking the label expansion of PD-1 inhibitor Libtayo for the treatment of patients with recurrent or metastatic cervical cancer has been granted Priority Review.
FDA Accepts Bristol Myers (BMY) sBLAs for Opdivo Combo for ESCC
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLAs for Opdivo-based combinations as a potential treatment for esophageal squamous cell carcinoma.
Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids
by Zacks Equity Research
FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.
OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed
by Zacks Equity Research
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO Recommendation
by Zacks Equity Research
Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Continental Resources, O'Reilly Automotive, Darling Ingredients and The Mosaic Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Continental Resources, O'Reilly Automotive, Darling Ingredients and The Mosaic Co
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
by Zacks Equity Research
Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.